Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $67 | $60 | $49 | $74 |
| % Growth | 12.5% | 21.5% | -33.1% | – |
| Cost of Goods Sold | $1 | $57 | $50 | $46 |
| Gross Profit | $66 | $3 | -$0 | $28 |
| % Margin | 97.9% | 5.5% | -0.8% | 38.2% |
| R&D Expenses | $75 | $79 | $77 | $72 |
| G&A Expenses | $0 | $0 | $11 | $0 |
| SG&A Expenses | $35 | $38 | $44 | $43 |
| Sales & Mktg Exp. | $0 | $0 | $33 | $0 |
| Other Operating Expenses | $51 | $0 | $0 | $0 |
| Operating Expenses | $161 | $117 | $121 | $115 |
| Operating Income | -$95 | -$114 | -$121 | -$87 |
| % Margin | -140.7% | -189.8% | -245.8% | -117.5% |
| Other Income/Exp. Net | $1 | $4 | $3 | $10 |
| Pre-Tax Income | -$94 | -$110 | -$118 | -$77 |
| Tax Expense | -$2 | $2 | -$2 | $2 |
| Net Income | -$91 | -$112 | -$116 | -$79 |
| % Margin | -135.3% | -186.2% | -235.5% | -106.6% |
| EPS | -0.25 | -0.33 | -0.36 | -0.26 |
| % Growth | 24.2% | 8.3% | -38.5% | – |
| EPS Diluted | -0.25 | -0.33 | -0.36 | -0.26 |
| Weighted Avg Shares Out | 364 | 335 | 323 | 305 |
| Weighted Avg Shares Out Dil | 364 | 335 | 323 | 305 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $4 | $3 | $10 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $9 | $12 | $11 | $12 |
| EBITDA | -$85 | -$102 | -$107 | -$75 |
| % Margin | -125.5% | -169.9% | -216.8% | -101.6% |